

# Ruxolitinib (phosphate)

Catalog No: tcsc0326



## Available Sizes

**Size:** 5mg

**Size:** 10mg

**Size:** 50mg

**Size:** 100mg

**Size:** 200mg

**Size:** 500mg

**Size:** 1g



## Specifications

**CAS No:**

1092939-17-7

**Formula:**

$C_{17}H_{21}N_6O_4P$

**Pathway:**

Epigenetics; Stem Cell/Wnt; JAK/STAT Signaling; Autophagy; Autophagy

**Target:**

JAK; JAK; JAK; Autophagy; Mitophagy

**Purity / Grade:**

>98%

**Solubility:**

DMSO :  $\geq 31$  mg/mL (76.66 mM); H<sub>2</sub>O : 5.4 mg/mL (13.35 mM; Need ultrasonic and warming)

**Alternative Names:**

INCB018424 phosphate

**Observed Molecular Weight:**

404.36


**Product Description**

Ruxolitinib (phosphate) is the first potent **JAK1/2** inhibitor with **IC<sub>50</sub>** values of 3.3 nM/2.8 nM, more than 130-fold selectivity for JAK1/2 versus JAK3.

IC50 & Target: IC50: 3.3 nM (JAK1), 2.8 nM (JAK2)

**In Vitro:** Ruxolitinib (INCB018424) potently and selectively inhibits JAK2V617F-mediated signaling and proliferation. Ruxolitinib inhibits the growth of HEL cells with EC<sub>50</sub> of 186 nM. Ruxolitinib markedly increases apoptosis in Ba/F3-EpoR-JAK2V617F cell system, and inhibits hematopoietic progenitor cell proliferation in primary MPN patient samples<sup>[1]</sup>.

**In Vivo:** Ruxolitinib (180 mg/kg, p.o.) reduces the tumor burden of mice inoculated with JAK2V617F-expressing cells without causing anemia or lymphopenia<sup>[1]</sup>.



All products are for RESEARCH USE ONLY. Not for diagnostic & therapeutic purposes!